Silencing of miR-34a Attenuates Cardiac Dysfunction in a Setting of Moderate, but Not Severe, Hypertrophic Cardiomyopathy

• Bianca C. Bernardo ,

  * E-mail: bianca.bernardo@bakeridi.edu.au (BCB); julie.mcmullen@bakeridi.edu.au (JRM)

  Affiliation Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

  ⨯
• Xiao-Ming Gao,

  Affiliation Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

  ⨯
• Yow Keat Tham,

  Affiliation Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

  ⨯
• Helen Kiriazis,

  Affiliation Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

  ⨯
• Catherine E. Winbanks,

  Affiliation Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

  ⨯
• Jenny Y. Y. Ooi,

  Affiliation Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

  ⨯
• Esther J. H. Boey,

  Affiliation Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

  ⨯
• Susanna Obad,

  Affiliation Santaris Pharma, Horsholm, Denmark

  ⨯
• Sakari Kauppinen,

  Affiliation Department of Haematology, Aalborg University Hospital, Copenhagen, Denmark

  ⨯
• Paul Gregorevic,

  Affiliation Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

  ⨯
• Xiao-Jun Du,

  Affiliation Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

  ⨯
• Ruby C. Y. Lin,

  Affiliation Ramaciotti Centre for Genomics, School of Biotechnology & Biomolecular Sciences, University of New South Wales, Sydney, New South Wales, Australia

  ⨯
• Julie R. McMullen

  * E-mail: bianca.bernardo@bakeridi.edu.au (BCB); julie.mcmullen@bakeridi.edu.au (JRM)

  Affiliations Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia, Departments of Medicine Monash University, Clayton, Victoria, Australia, Departments of Physiology, Monash University, Clayton, Victoria, Australia

  ⨯